A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-499 in Type 2 Diabetic Nephropathy Patients

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 170 participants.

Also called NCT01487109

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 170 participants (enrolled count) (from the registry)
Sponsor
Concert Pharmaceuticals (from the registry)
Registry
  • NCT NCT01487109
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01487109. Randomized; double masking; primary purpose treatment. Start 2012-01 (registry gives no type); primary completion 2015-01 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
A Phase 2 Study to Evaluate the Safety and Efficacy of CTP-499 in Type 2 Diabetic Nephropathy Patients
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
CTP-499
Intervention (Drug)
Placebo
Lead sponsor
Concert Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct01487109
Content hash
49deeddfabfd640171b0c96cd80db66d82a41e3ef34c38845fdc831577af9e03